MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
Country |
 USA |
IPO year |
2010 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
32.7 M |
Market Cap[1] |
$ 521 M |
EBITDA (LTM) |
$ -26.4 M |
P/E (LTM) |
- |
P/S (LTM) |
6.19 |
EPS (LTM) |
-0.9 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Graybug Vision
GRAY
|
- | -11.23 % | $ 9.65 M | Nasdaq Global Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.64 | -1.89 % | $ 1.09 B | Nasdaq Global Select Market |  Canada |
 |
ADMA Biologics
ADMA
|
$ 16.45 | 0.43 % | $ 3.92 B | Nasdaq Global Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
ANI Pharmaceuticals
ANIP
|
$ 76.75 | 0.85 % | $ 1.48 B | Nasdaq Global Market,SPB | USA |
 |
Apellis Pharmaceuticals
APLS
|
$ 19.93 | -1.14 % | $ 2.51 B | Nasdaq Global Select Market,SPB | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Aptorum Group Limited
APM
|
$ 0.83 | 4.23 % | $ 4.53 M | Nasdaq Global Select Market | China |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Burford Capital Limited
BUR
|
$ 8.4 | -1.81 % | $ 1.39 B | NYSE | Britain |
 |
Axsome Therapeutics
AXSM
|
$ 163.82 | -0.14 % | $ 8.15 B | Nasdaq Global Market,SPB | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
BridgeBio Pharma
BBIO
|
$ 66.98 | 3.8 % | $ 12.8 B | Nasdaq Global Select Market,SPB | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.88 | 2.51 % | $ 908 M | Nasdaq Capital Market |  Israel |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 60.75 | 3.79 % | $ 11.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
CTI BioPharma Corp.
CTIC
|
- | - | $ 1.2 B | Nasdaq Capital Market | USA |
 |
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
- | -5.98 % | $ 34.1 M | Nasdaq Capital Market | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Cabaletta Bio
CABA
|
$ 3.41 | 4.77 % | $ 3.98 M | Nasdaq Global Select Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 25.71 | -0.5 % | $ 688 M | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Codexis
CDXS
|
$ 1.1 | 12.24 % | $ 80.7 M | Nasdaq Global Select Market | USA |
 |
Certara
CERT
|
$ 7.33 | 1.24 % | $ 1.18 B | Nasdaq Global Select Market | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | USA |
 |
Evofem Biosciences
EVFM
|
- | 7.55 % | $ 38.1 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.